Authorized purpose: Provides stand-alone analysis, measurement, and reporting of DICOM vascular-ultrasound images from carotid and lower-limb arteries.
Clinical role
Image analysis software that segments vessel walls, measures carotid intima-media thickness in B-Mode images and finds Doppler velocities, then generates a vascular ultrasound report that a qualified clinician reviews, can modify, and approves after quality control.
Images and patients
Ultrasound · Vascular
Key limitation
Keep in mind: Qualified-clinician review, approval, and quality control are required; it is not independent medical advice or treatment guidance.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provides stand-alone analysis, measurement, and reporting of DICOM vascular-ultrasound images from carotid and lower-limb arteries.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Vascular Input: DICOM vascular ultrasound including carotid B-mode and Doppler images plus annotations.
Who uses it?Intended users: Trained medical professionals, including physicians and medical technicians.
What does the software produce?Output: Vessel-wall segmentation, carotid IMT, PSV/EDV, annotation reading, lower-limb waveform classification, stenosis drawings, and vascular-ultrasound reports.
What is its most important limitation?Key limitation: Qualified-clinician review, approval, and quality control are required; it is not independent medical advice or treatment guidance.
Clinical takeaway. Clinical role: Provides stand-alone analysis, measurement, and reporting of DICOM vascular-ultrasound images from carotid and lower-limb arteries.
Evidence takeaway. Evidence from the reviewed source record: Testing included 205 carotid images, annotation datasets of 783-1,432 images, 1,117 PSV/EDV images, and 150 waveform images; reported metrics include IMT correlation 0.89 and waveform accuracy 93%.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provides stand-alone analysis, measurement, and reporting of DICOM vascular-ultrasound images from carotid and lower-limb arteries.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Image analysis software that segments vessel walls, measures carotid intima-media thickness in B-Mode images and finds Doppler velocities, then generates a vascular ultrasound report that a qualified clinician reviews, can modify, and approves after quality control.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The software uses proprietary algorithms for image analysis, including segmentation of vessel walls and measurement of the intima-media thickness (IMT) of the carotid artery in B-Mode images and finding peak systolic and end diastolic velocities (PSV and EDV) from Doppler images." … "The software generates a vascular ultrasound report based on the image analysis results to be reviewed and approved by a qualified clinician after performing quality control.". Read from the exact FDA decision document on 2026-11-14.
Anyone in the general population who receives vascular ultrasound of the carotid or lower limb arteries; the FDA document does not specify a facility type.
Exact FDA submission
Checked 2026-11-14
Packet wording: "See-Mode AVA (Augmented Vascular Analysis) is a stand-alone, image processing software for analysis, measurement, and reporting of DICOM-compliant vascular ultrasound images obtained from carotid and lower limb arteries." … "target population of the device is anyone". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Testing included 205 carotid images, annotation datasets of 783-1,432 images, 1,117 PSV/EDV images, and 150 waveform images; reported metrics include IMT correlation 0.89 and waveform accuracy 93%.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
AVA (Augmented Vascular Analysis) regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K201369
Samplen=355
IndependenceIndependence not established
K201369
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K201369. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM vascular ultrasound including carotid B-mode and Doppler images plus annotations.
Scope: Exact FDA submission. FDA packet input scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes See-Mode AVA as a software program running on a cloud platform, accessible within a web browser, with client software designed to run on a standard desktop or laptop computer. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "See-Mode AVA benefits from the advancements of cloud computing and is a software program running on a cloud platform and can be accessed using multiple platforms, including Windows." … "The software runs on a standard off-the-shelf computer and is accessible within a web browser.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Scope: Exact FDA submission. FDA packet output scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes See-Mode AVA as a software program running on a cloud platform, accessible within a web browser, with client software designed to run on a standard desktop or laptop computer. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "See-Mode AVA benefits from the advancements of cloud computing and is a software program running on a cloud platform and can be accessed using multiple platforms, including Windows." … "The software runs on a standard off-the-shelf computer and is accessible within a web browser.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
ACR AI Central provides an exact-submission model card for AVA (Augmented Vascular Analysis); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K201369 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: EdgeFlow UW20 is a wearable ultrasound system for noninvasive periodic bladder-volume measurement in adults with BMI no greater than 30.
Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.
Authorized purpose: Provides AI-assisted cardiac, lung and abdominal quality feedback and measurements; users remain responsible for scan quality and diagnosis and must not rely solely on the software.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.